Evidence map›Paper›PMID 41580610›Full record

ArticleClinical proteomics2026

ProteoBoostR: an interactive framework for supervised machine learning in clinical proteomics.

Annika Topitsch, Niko Pinter, Tilman Werner, Katja Nelson, Tobias Fretwurst, Oliver Schilling

Abstract read
In one paragraph

Article in Clinical proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Unveiling the Diagnostic Value and Potential Therapeutic Targets of Phenylalanine Metabolism in Pancreatic Cancer via Integrated Multi-Omics and Machine Learning.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Annika Topitsch *Institute for Surgical Pathology, Medical Center, Medical Faculty, University of Freiburg, University of Freiburg, 79106, Freiburg, Germany.
Niko Pinter *Institute for Surgical Pathology, Medical Center, Medical Faculty, University of Freiburg, University of Freiburg, 79106, Freiburg, Germany.
Tilman WernerInstitute for Surgical Pathology, Medical Center, Medical Faculty, University of Freiburg, University of Freiburg, 79106, Freiburg, Germany.
Katja NelsonDepartment of Oral and Maxillofacial Surgery/Translational Implantology, Medical Center, Medical Faculty, University of Freiburg, University of Freiburg, 79106, Freiburg, Germany.
Tobias FretwurstDepartment of Oral and Maxillofacial Surgery/Translational Implantology, Medical Center, Medical Faculty, University of Freiburg, University of Freiburg, 79106, Freiburg, Germany.
Oliver SchillingInstitute for Surgical Pathology, Medical Center, Medical Faculty, University of Freiburg, University of Freiburg, 79106, Freiburg, Germany. oliver.schilling@uniklinik-freiburg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMass spectrometry-based proteomics enables high-throughput quantification of thousands of proteins in clinical samples, fueling biomarker discovery for disease diagnosis and prognosis. However, leveraging complex proteomic profiles for predictive modeling often requires advanced machine learning (ML) expertise that many biomedical researchers lack. User-friendly tools are needed to apply state-of-the-art ML algorithms to proteomics data. XGBoost is a powerful tree-based ML algorithm known for high accuracy in classification tasks, and has been successfully used to classify cancer subtypes from multi-omics data.

methodsWe developed ProteoBoostR, a Shiny application that streamlines supervised ML on protein abundance datasets. It allows researchers to train, evaluate and apply XGBoost classification models through an interactive web interface, without requiring coding.

resultsWe demonstrate the application of ProteoBoostR for the classification of proteomic subtypes across two independent datasets of glioblastoma multiforme, and for the detection of lung adenocarcinoma in serum. These application examples illustrate how ProteoBoostR can harness proteomic patterns for the stratification of patients.

conclusionsProteoBoostR is an open-source application that empowers proteomics researchers to perform advanced ML classification. It can be readily applied to other proteomic datasets and disease contexts, promoting reproducible ML analyses in proteomics and accelerating the translation of omics-based classifiers into clinical research.

Indexed as

Classification modelsMachine learningPersonalized medicineProteomicsXGBoost

Identifiers

PMID41580610
PMCPMC12849323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.